OncoMatch/Clinical Trials/NCT07332455
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Is NCT07332455 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GSK5471713 for neoplasms, prostate.
Treatment: GSK5471713 — This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen deprivation therapy
prostate cancer progression while on Androgen deprivation therapy (ADT)
Must have received: androgen receptor pathway inhibitor — Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC)
progression on ADT and >=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC)
Must have received: taxane
received 1-2 prior taxane based chemotherapy regimens
Cannot have received: androgen receptor degrader
Prior therapy with Androgen receptor (AR) Degrader targeted therapy
Lab requirements
Cardiac function
Impaired cardiac function or clinically significant cardiac disease [excluded]
Impaired cardiac function or clinically significant cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Grand Rapids, Michigan
- GSK Investigational Site · West Valley City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify